JAZZ Jazz Pharmaceuticals PLC

USD 109.70 0.69 0.632969
Icon

Jazz Pharmaceuticals PLC (JAZZ) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 109.70

+0.69 (+0.63)%

USD 6.66B

0.40M

USD 189.00(+72.29%)

USD 150.00 (+36.74%)

Icon

JAZZ

Jazz Pharmaceuticals PLC (USD)
COMMON STOCK | NSD
USD 109.70
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 6.66B

USD 150.00 (+36.74%)

USD 109.70

Jazz Pharmaceuticals PLC (JAZZ) Stock Forecast

Show ratings and price targets of :
USD 189.00
(+72.29%)

Based on the Jazz Pharmaceuticals PLC stock forecast from 11 analysts, the average analyst target price for Jazz Pharmaceuticals PLC is USD 189.00 over the next 12 months. Jazz Pharmaceuticals PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Jazz Pharmaceuticals PLC is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Jazz Pharmaceuticals PLC’s stock price was USD 109.70. Jazz Pharmaceuticals PLC’s stock price has changed by +6.16% over the past week, +1.60% over the past month and -16.20% over the last year.

No recent analyst target price found for Jazz Pharmaceuticals PLC
No recent average analyst rating found for Jazz Pharmaceuticals PLC

Company Overview Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hyperso...Read More

https://www.jazzpharma.com

Waterloo Exchange, Dublin, Ireland, D04 E5W7

2,800

December

USD

USA

Adjusted Closing Price for Jazz Pharmaceuticals PLC (JAZZ)

Loading...

Unadjusted Closing Price for Jazz Pharmaceuticals PLC (JAZZ)

Loading...

Share Trading Volume for Jazz Pharmaceuticals PLC Shares

Loading...

Compare Performance of Jazz Pharmaceuticals PLC Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for JAZZ

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Jazz Pharmaceuticals PLC (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing JAZZ

Symbol Name JAZZ's Weight Expense Ratio Price(Change) Market Cap
HMMJ-U:CA
Horizons Marijuana Life S.. 11.78 % 0.00 % 0.00 (0.00%) USD0.09B

Frequently Asked Questions About Jazz Pharmaceuticals PLC (JAZZ) Stock

Based on ratings from 11 analysts Jazz Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 14 buy, sell and 3 hold ratings.

Unfortunately we do not have enough data on JAZZ's stock to indicate if its a good dividend stock.

Based on targets from 11 analysts, the average taret price for JAZZ is USD 189.00 over the next 12 months. The maximum analyst target price is USD 230 while the minimum anlayst target price is USD 113.

JAZZ stock's Price/Earning ratio is 21.86. Our analysis grades JAZZ stock's Price / Earning ratio at F. This means that JAZZ stock's Price/Earning ratio is above 73% of the stocks in the Biotechnology sector in the NSD exchange. Based on this JAZZ may be a overvalued for its sector.

The last closing price of JAZZ's stock was USD 109.70.

The most recent market capitalization for JAZZ is USD 6.66B.

Based on targets from 11 analysts, the average taret price for JAZZ is projected at USD 189.00 over the next 12 months. This means that JAZZ's stock price may go up by +72.29% over the next 12 months.

Following are ETFs with the highest allocation to Jazz Pharmaceuticals PLC's stock :

HMMJ-U:CA

As per our most recent records Jazz Pharmaceuticals PLC has 2,800 Employees.

Jazz Pharmaceuticals PLC's registered address is Waterloo Exchange, Dublin, Ireland, D04 E5W7. You can get more information about it from Jazz Pharmaceuticals PLC's website at https://www.jazzpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...